Mycodern Spolka Akcyjna
0.78
PLN
0.00
(0.00%)
Mycodern Spolka Akcyjna
NEWCONNECT:MCD
(NewConnect)
Recent
price
0.78
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mycodern Spolka Akcyjna operates as a nutraceutical and functional food company specializing in the formulation, manufacturing, marketing, and distribution of dietary supplements and wellness products. The company develops and sells a diversified portfolio of consumer health products, including sugar-free and vegan functional gummies; hemp-derived extracts and cannabidiol (CBD) oils; sleep-support supplements containing melatonin; immunity formulations enriched with vitamin D3 and zinc; cognitive and focus supplements featuring vitamin B complexes; multivitamin blends; and beauty nutraceuticals formulated with biotin and zinc for hair, skin, and nail health, commercialized under proprietary brand names such as Gummley and Hempley. In addition to proprietary retail brands, the company offers end-to-end B2B services, including contract manufacturing, custom private-label formulation, white-label production, packaging, e-commerce logistics, and wholesale supply for third-party wellness and pharmaceutical brands. Founded in 2011 and headquartered in Warsaw, Poland, Mycodern Spolka Akcyjna distributes its products through pharmacies, specialized health stores, retail drugstores, and direct-to-consumer digital channels across Poland and the broader European market. In recent corporate developments, the company executed a comprehensive strategic transformation from its legacy commercial printing and media services to the wellness and nutraceutical sector, anchored by the 100% acquisition of Gdańsk-based supplement company Hempley Sp. z o.o. and the formal corporate rebranding from Median Polska S.A. to Mycodern Spolka Akcyjna. Following this strategic pivot, the company initiated formal debt restructuring and arrangement proceedings to stabilize its balance sheet and streamline operations, leading to the regulatory resumption of trading for its shares on the Warsaw Stock Exchange NewConnect market.